Indivior Pharmaceuticals, Inc. (INDV)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$175.0M
Cash & Equivalents
$9.0M
Quarterly Burn Rate
58 mo
Est. Cash Runway
$4,525M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (4 Assets)

DrugPhaseIndications
NALMEFENE HYDROCHLORIDE
OPVEE 		APPROVED —
BUPRENORPHINE
SUBLOCADE 		APPROVED —
BUPRENORPHINE HYDROCHLORIDE
BUPRENEX 		NDA —
BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
SUBOXONE 		NDA —

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for INDV.

SEC EDGAR Filings

All SEC filings for Indivior Pharmaceuticals, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.